Success Metrics

Clinical Success Rate
77.8%

Based on 14 completed trials

Completion Rate
78%(14/18)
Active Trials
4(11%)
Results Posted
36%(5 trials)
Terminated
4(11%)

Phase Distribution

Ph phase_1
1
3%
Ph not_applicable
17
49%
Ph phase_3
8
23%
Ph early_phase_1
1
3%
Ph phase_2
5
14%

Phase Distribution

2

Early Stage

5

Mid Stage

8

Late Stage

Phase Distribution32 total trials
Early Phase 1First-in-human
1(3.1%)
Phase 1Safety & dosage
1(3.1%)
Phase 2Efficacy & side effects
5(15.6%)
Phase 3Large-scale testing
8(25.0%)
N/ANon-phased studies
17(53.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.0%

14 of 20 finished

Non-Completion Rate

30.0%

6 ended early

Currently Active

4

trials recruiting

Total Trials

35

all time

Status Distribution
Active(7)
Completed(14)
Terminated(6)
Other(8)

Detailed Status

Completed14
unknown8
Terminated4
Recruiting4
Not yet recruiting3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
35
Active
4
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (3.1%)
Phase 11 (3.1%)
Phase 25 (15.6%)
Phase 38 (25.0%)
N/A17 (53.1%)

Trials by Status

completed1440%
terminated411%
recruiting411%
withdrawn26%
unknown823%
not_yet_recruiting39%

Recent Activity

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more
NCT04871035

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

Recruiting
NCT06562803Not Applicable

Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis

Recruiting
NCT06483139

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Recruiting
NCT03994783Phase 3

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

Terminated
NCT00120263Not Applicable

Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma

Completed
NCT06855667Not Applicable

Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.

Not Yet Recruiting
NCT06698991Not Applicable

Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children

Not Yet Recruiting
NCT06652516Not Applicable

Comparison Between Centrifugation Based and Membrane Based Plasma Exchange

Completed
NCT04302805Phase 3

rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)

Completed
NCT06355726Not Applicable

Efficacy of Plasma Exchange Therapy vs Standard Medical Therapy in Severe Alcoholic Hepatitis With High Discriminant Function

Recruiting
NCT03897205Phase 2

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

Completed
NCT06276907Not Applicable

An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response

Not Yet Recruiting
NCT02622854Not Applicable

Plasma Exchange vs Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis

Completed
NCT04374539Phase 2

Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial

Terminated
NCT04431375Not Applicable

Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

Unknown
NCT04949698

Risk Factors and the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic Microangiopathies

Unknown
NCT02872142Phase 2

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

Completed
NCT04747106Not Applicable

Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure

Unknown
NCT04550611Not Applicable

Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome

Unknown
NCT00987389Phase 3

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

Completed

Drug Details

Intervention Type
DEVICE
Total Trials
35